Please assess the completion status of the following clinical trial:

Trial Title: Phase II Randomized Study on Locally Advanced NSCLC Escalated Dose on Individual Basis Treatment With Radiochemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histological or cytological diagnosis of NSCLC stage IIIA-B.~* Nonresectable or medically inoperable patients.~* No prior chemo- or radiotherapy for NSCLC.~* PS 0-1.~* FEV1 \> 1 l or \> 40% and CO diffusion capacity \> 40%.~* Patient compliance and geographic proximity that allow adequate follow-up.~* Adequate bone marrow reserve: WBCC \>3.0, platelets \>100, haemoglobin \> 100.~* Written informed concent.~* Effective use of contraception.~Exclusion Criteria:~* Excessive weight loss within 6 months (\> 10%).~* Supraclavicular nodes.~* Apical tumors-pancoast.~* T4 tumors with separate manifestations in different lobes.~* Evidence of active serious infections.~* Inadequate liver function.~* Inadequate kidney function.~* Pregnancy.~* Breast feeding.~* Serious concomitant systemic disorder.~* Second primary malignancy the last 5 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Arm A:Standard radiochemotherapy (Type: ACTIVE_COMPARATOR): Radiotherapy with 2 Gy per fractions 5 fractions a week to 68 Gy to the planning target volume. Three courses of cisplatin 75 mg/m2 day 1and vinorelbine 25 mg/m2 day 1+8. Two courses concomitant with radiation.
- Arm B Escalated radiochemotherapy (Type: EXPERIMENTAL): Radiotherapy with 2 Gy per fraction 5 or 6 times a week to 68-84 Gy to the planning target volume due to normal tissue tolerance constraints. Dose to lung tissue, esophagus and spinal cord will be considered. Three courses of cisplatin 75 mg/m2 day 1 and vinorelbine 25 mg/m2 day 1+8 will be given, two courses concomitant with radiation.

Based on this trial design, predict the completion outcome and termination type (if applicable).